High-Dose Antithrombin III in Severe SepsisBrian Warren, Ivan Novák, Pavel Chalupa et al.|JAMA|2001Cited by 1.4k
Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: A randomized, open-label, placebocontrolled multicenter trialCharles J. Fisher, Michael A. Catalano, Gus J. Slotman et al.|Critical Care Medicine|1994Cited by 490
From the bench to the bedside: the future of sepsis research. Executive summary of an American College of Chest Physicians, National Institute of Allergy and Infectious Disease, and National Heart, Lung, and Blood Institute Workshop.R. Phillip Dellinger, Samuel D. Wright, Steven M. Opal et al.|PubMed|1997Cited by 62